Drugs

, Volume 49, Supplement 2, pp 488–491 | Cite as

Initial Clinical Experience with Clinafloxacin in the Treatment of Serious Infections

  • Kenneth J. Tack
  • Nancy M. McGuire
  • Irene A. Eiseman
Miscellaneous Clinical Studies

Keywords

Cystic Fibrosis Cystic Fibrosis Patient Bronchiectasis Sparfloxacin Fleroxacin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Fuchs PC, Barry AL, Pfaller MA, et al. Multicenter evaluation of the in vitro activities of three new quinolones, sparfloxacin, CI-960, and PD 131,628, compared with the activity of ciprofloxacin against 5,252 clinical bacterial isolates. Antimicrob Agents Chemother 1991; 35 (4): 764–6PubMedCrossRefGoogle Scholar
  2. 2.
    Jones RN, Johnson DM. Modification for disk diffusion susceptibility testing criteria of CLF (CI-960, AM-1091, CP127371) and fleroxacin (RO 23-6240, AM-833) following studies with a challenge-panel of ciprofloxacin-resistant clinical isolates. Diagn Microbiol Infect Dis. In pressGoogle Scholar

Copyright information

© Adis International Limited 1995

Authors and Affiliations

  • Kenneth J. Tack
    • 1
  • Nancy M. McGuire
    • 1
  • Irene A. Eiseman
    • 1
  1. 1.Division of Warner-Lambert CompanyParke-Davis Pharmaceutical ResearchAnn ArborUSA

Personalised recommendations